Robert Duggan Buys Shares of Summit Therapeutics Inc. $SMMT
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Robert Duggan, Co-Chief Executive Officer at Summit Therapeutics Inc. ($SMMT), bought 3,810,000 shares at an average price of $13.12, for a total transaction of $49.99 million. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Summit Therapeutics Inc. Stock Up 5.0%
Shares of Summit Therapeutics Inc. ($SMMT) traded around $14.41 on Saturday, up 5.0% for the day.
Summit Therapeutics Inc. Earnings
Analysts Set New Price Targets
About Summit Therapeutics Inc.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
Get Summit Therapeutics Inc. alerts
New 13F filings, insider trades, and analyst moves on $SMMT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.